Hyperion DeFi (NASDAQ:HYPD) CFO David Knox Acquires 27,950 Shares of Stock

Hyperion DeFi, Inc. (NASDAQ:HYPD) CFO David Knox acquired 27,950 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The shares were bought at an average price of $3.59 per share, with a total value of $100,340.50. Following the transaction, the chief financial officer owned 327,950 shares in the company, valued at $1,177,340.50. This represents a 9.32% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Hyperion DeFi Price Performance

NASDAQ:HYPD opened at $3.96 on Tuesday. Hyperion DeFi, Inc. has a 12-month low of $0.85 and a 12-month high of $17.18. The firm has a market cap of $32.35 million, a price-to-earnings ratio of -0.98 and a beta of 2.69. The company’s 50-day moving average is $4.45 and its two-hundred day moving average is $7.57. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 0.11.

Hyperion DeFi (NASDAQ:HYPD) last posted its quarterly earnings data on Friday, November 14th. The company reported $0.05 earnings per share for the quarter. The firm had revenue of $0.36 million during the quarter. Research analysts expect that Hyperion DeFi, Inc. will post -41.6 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Wall Street Zen upgraded Hyperion DeFi from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Chardan Capital set a $7.75 price target on Hyperion DeFi and gave the company a “buy” rating in a report on Wednesday, December 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Wednesday, October 8th. Zacks Research raised shares of Hyperion DeFi to a “hold” rating in a research report on Monday, December 29th. Finally, Cantor Fitzgerald assumed coverage on shares of Hyperion DeFi in a report on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 target price for the company. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Hyperion DeFi has an average rating of “Hold” and an average price target of $4.58.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.